

FOI 2793

19th December 2024

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Question 1a:

How many patients were treated with the following drugs for the following diseases from the start of Jul 2024 to the end of Sept 2024?

Please use the latest available 3 months if Jul to Sept is not available and specify which 3 months has been used. Please ignore any cells which have been blanked out.

Response:

Drug Name	Plaque psoriasis	Crohn's Disease	Ulcerative colitis	Psoriatic arthritis	Ankylosing spondylitis (inc. axial spondylitis)	Rheumatoid arthritis
Adalimumab	243	131	61	209	191	162
Apremilast	0			0		
Bimekizumab	12			0	1	
Brodalumab	6					
Certolizumab Pegol	6			31	24	20
Deucravacitinib	0					
Etanercept	2			69	35	111
Guselkumab	64			15		
Infliximab (Remicade)	0	0	0	0	0	0
Infliximab (Biosimilars)	3	49	50	10	6	6
Ixekizumab	106			38	15	
Risankizumab	83	0		3		
Secukinumab	28			94	59	
Tildrakizumab	7					
Ustekinumab	26	70	32	0		
Upadacitinib		9	9	4	5	14
Vedolizumab		48	52			
Filgotinib			0			0
Golimumab			1	27	31	18
Mirikizumab			0			
Ozanimod			0			
Etrasimod			0			
Tofacitinib			4	4	0	4

Baricitinib						40
Rituximab						87
Sarilumab						21
Tocilizumab						33

Question 1b:

How many patients were treated with Ustekinumab and its biosimilars from the start of Jul 2024 to the end of Sept 2024?

Please use the latest available 3 months if Jul to Sept is not available and specify which 3 months has been used.

Response:

Drug Name	Plaque psoriasis	Crohn's Disease	Ulcerative colitis	Psoriatic arthritis
Ustekinumab (Stelara)	26	70	32	0
Ustekinumab (Pyzchiva)	0	0	0	0
Ustekinumab (Uzpruvo)	0	0	0	0
Ustekinumab (Wezenla)	0	0	0	0

Email: Foi.Team@Southerntrust.hscni.net